FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089513510> ?p ?o ?g. }

• W2089513510 endingPage "1476" @default.
• W2089513510 startingPage "1475" @default.
• W2089513510 abstract "Both growth hormone and its target hormone, insulin growth factor-I (IGF-1), decline with age.1 This decline with age has been attributed both to a decrease in the secretions of growth hormone releasing hormone and its activity, as well as to an increase in somatostatin from the hypothalamus. Studies in both animals and humans with L-arginine, which is thought to inhibit somatostatin secretion, have demonstrated a vigorous growth hormone response in older persons.2-4 In addition, somatostatin antisera increased growth hormone to a greater extent in older than in younger rodents.5 In this issue of JAGS, Mulligan et al.6 demonstrate that somatostatin inhibits growth hormone secretion in both young and older persons. This demonstrates that the pituitary response to somatostatin remains intact with aging in humans. The enthusiasm for studying growth hormone in older persons increased exponentially approximately a decade ago when Rudman,7 in the pages of JAGS, suggested that a growth hormone “menopause” occurred with aging. He pointed out that many of the physiological changes of aging were similar to the changes associated with growth hormone deficiency. In his original study, he demonstrated some positive effects of growth hormone therapy given to men for 6 months.8 Unfortunately, when the therapy was continued for 12 months, side effects such as carpal tunnel syndrome, gynecomastia, and arthralgias limited the ability of most persons to tolerate growth hormone therapy.9 A number of subsequent studies have demonstrated that in older men and women growth hormone increased muscle mass but not strength.10-15 Exercise was more efficacious than was growth hormone at increasing muscle strength, and growth hormone did not enhance the effects of exercise.15 Other effects of growth hormone included an increase in resting energy expenditure and a decrease in body fat. However, in all of these studies, side effects such as carpal tunnel syndrome, edema, arthralgias, myalgias, and gynecomastia limited the use of growth hormone in many older individuals. Growth hormone has been used to reverse catabolism in some older persons with malnutrition.16, 17 A recent report has described a malnourished man in his 80s who had a marked decrease in growth hormone receptors.18 This decline in growth hormone receptors with malnutrition may be a key to why pharmacological doses of growth hormone may be useful in the treatment of severe malnutrition in older persons. Because malnutrition is a major health problem of older individuals,19 further studies on whether growth hormone can decrease hospital stay or mortality and improve functional status in malnourished older persons are justified. Some have thought that the large number of side-effects associated with growth hormone administration in older persons is a result of the pharmacological nature of the treatment. This has led to an enthusiastic effort to find a mechanism to produce physiological increases in circulating growth hormone levels. Oral growth hormone secretagogues have now been developed. Thorner et al.20 demonstrated that MK-771 can produce a physiological increase in growth hormone. Long-term studies on whether this compound can increase strength without producing unacceptable side effects are not yet published. Several years ago, Denckla21 suggested that the pituitary produced a “death hormone.” Could growth hormone administration to older persons result in a shortened life span? The Snell dwarf mutant mouse, which lacks growth hormone, lives longer than its nonmutant controls that produce growth hormone normally.22 Growth hormone administration to older rodents does not increase life span.23 A study in Paris found that males with higher basal growth hormone levels were more likely to die than were those with lower growth hormone levels.24 These studies do not champion the use of growth hormone as a hormonal “fountain of youth.” See also p 1422 It is possible that increasing tissue IGF-1 may prove more effective at increasing frailty. Baumgartner et al.25 showed that appendicular skeletal mass was best predicted by IGF-1, free testosterone, and physical activity in older men, and by IGF-1 and physical activity in women. Testosterone increases tissue IGF-1 levels26 and has been shown to increase muscle strength in older men27, 28 and muscle mass in women.29 Testosterone, although not side-effect free, seems to have a better safety track record than does growth hormone in older persons.30 At present, the case for growth hormone replacement in healthy older persons is certainly “not proven.” Growth hormone may well have a place in the management of severely ill, malnourished older individuals. The “effect” of oral growth hormone secretagogues that produce physiological levels of growth hormone remains to be determined. It is possible that the decline in growth hormone and IGF-1 represents a protective mechanism that results in prolongation of life span. Further longitudinal epidemiological studies determining whether the decline in growth hormone and IGF-1 with aging has positive or negative effects on health status and life span are needed." @default.
• W2089513510 created "2016-06-24" @default.
• W2089513510 creator A5006935353 @default.
• W2089513510 date "1999-12-01" @default.
• W2089513510 modified "2023-10-13" @default.
• W2089513510 title "Growth Hormone: Fountain of Youth or Death Hormone?" @default.
• W2089513510 cites W1973979382 @default.
• W2089513510 cites W1985592735 @default.
• W2089513510 cites W1989458934 @default.
• W2089513510 cites W1989657845 @default.
• W2089513510 cites W1995707695 @default.
• W2089513510 cites W2002215523 @default.
• W2089513510 cites W2003620064 @default.
• W2089513510 cites W2003627100 @default.
• W2089513510 cites W2008745673 @default.
• W2089513510 cites W2022705586 @default.
• W2089513510 cites W2024959979 @default.
• W2089513510 cites W2028182259 @default.
• W2089513510 cites W2038179111 @default.
• W2089513510 cites W2042178933 @default.
• W2089513510 cites W2066519654 @default.
• W2089513510 cites W2078434653 @default.
• W2089513510 cites W2107421890 @default.
• W2089513510 cites W2128083810 @default.
• W2089513510 cites W2133060717 @default.
• W2089513510 cites W2138364455 @default.
• W2089513510 cites W2158378127 @default.
• W2089513510 cites W2162475967 @default.
• W2089513510 cites W2315987042 @default.
• W2089513510 doi "https://doi.org/10.1111/j.1532-5415.1999.tb01572.x" @default.
• W2089513510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10591247" @default.
• W2089513510 hasPublicationYear "1999" @default.
• W2089513510 type Work @default.
• W2089513510 sameAs 2089513510 @default.
• W2089513510 citedByCount "31" @default.
• W2089513510 countsByYear W20895135102012 @default.
• W2089513510 countsByYear W20895135102014 @default.
• W2089513510 countsByYear W20895135102015 @default.
• W2089513510 countsByYear W20895135102020 @default.
• W2089513510 countsByYear W20895135102021 @default.
• W2089513510 countsByYear W20895135102022 @default.
• W2089513510 crossrefType "journal-article" @default.
• W2089513510 hasAuthorship W2089513510A5006935353 @default.
• W2089513510 hasConcept C121608353 @default.
• W2089513510 hasConcept C126322002 @default.
• W2089513510 hasConcept C134018914 @default.
• W2089513510 hasConcept C2776297358 @default.
• W2089513510 hasConcept C2777433750 @default.
• W2089513510 hasConcept C2780275930 @default.
• W2089513510 hasConcept C2781042741 @default.
• W2089513510 hasConcept C2984496839 @default.
• W2089513510 hasConcept C530470458 @default.
• W2089513510 hasConcept C71315377 @default.
• W2089513510 hasConcept C71924100 @default.
• W2089513510 hasConceptScore W2089513510C121608353 @default.
• W2089513510 hasConceptScore W2089513510C126322002 @default.
• W2089513510 hasConceptScore W2089513510C134018914 @default.
• W2089513510 hasConceptScore W2089513510C2776297358 @default.
• W2089513510 hasConceptScore W2089513510C2777433750 @default.
• W2089513510 hasConceptScore W2089513510C2780275930 @default.
• W2089513510 hasConceptScore W2089513510C2781042741 @default.
• W2089513510 hasConceptScore W2089513510C2984496839 @default.
• W2089513510 hasConceptScore W2089513510C530470458 @default.
• W2089513510 hasConceptScore W2089513510C71315377 @default.
• W2089513510 hasConceptScore W2089513510C71924100 @default.
• W2089513510 hasIssue "12" @default.
• W2089513510 hasLocation W20895135101 @default.
• W2089513510 hasLocation W20895135102 @default.
• W2089513510 hasOpenAccess W2089513510 @default.
• W2089513510 hasPrimaryLocation W20895135101 @default.
• W2089513510 hasRelatedWork W173396347 @default.
• W2089513510 hasRelatedWork W2003682545 @default.
• W2089513510 hasRelatedWork W2055086560 @default.
• W2089513510 hasRelatedWork W2082468811 @default.
• W2089513510 hasRelatedWork W2094176660 @default.
• W2089513510 hasRelatedWork W2108596199 @default.
• W2089513510 hasRelatedWork W2411693876 @default.
• W2089513510 hasRelatedWork W2475144847 @default.
• W2089513510 hasRelatedWork W2944799263 @default.
• W2089513510 hasRelatedWork W4206014946 @default.
• W2089513510 hasVolume "47" @default.
• W2089513510 isParatext "false" @default.
• W2089513510 isRetracted "false" @default.
• W2089513510 magId "2089513510" @default.
• W2089513510 workType "article" @default.